BioPharma Dive June 8, 2023
Kristin Jensen

Dive Brief:

  • Upstream Bio has successfully navigated a rocky market for biotech startups to raise $200 million in fresh financing in a Series B round.
  • The company plans to use the funds to advance its experimental medicine UPB-101 into Phase 2 trials for asthma and chronic rhinosinusitis with nasal polyps and is also preparing for “a swift transition to Phase 3 development.” The drug is currently in Phase 1b testing for asthma.
  • Enavate Sciences and Venrock Healthcare Capital Partners led the latest round of financing, which also attracted new investors Bain Capital Life Sciences and Wellington Management. Enavate’s Edd Fleming and Venrock’s Alex Rosen joined Upstream’s board as well, the company said Thursday.

Dive Insight:

Led by Samantha...

Today's Sponsors


Today's Sponsor


Topics: Biotechnology, Investments, Pharma / Biotech, Trends
How digital health companies are capitalizing on the GLP-1 boom
Journalists Zero In on Bird Flu and Weight Loss Drugs
GLP-1 Agonists in Adolescents and Young Adults; Benefits of Cancer Drug Trials
Chasing the alchemy of trial diversity with a mix of culture change and practical mechanics
Ozempic Drug Semaglutide Could Protect Kidneys, Study Finds

Share This Article